Is calcium pyrophosphate crystal deposition disease a new disease in the list of rheumatic diseases with cardiovascular risk?
https://doi.org/10.47360/1995-4484-2026-258-262
Abstract
Calcium pyrophosphate deposition disease (CPPD) is a disease associated with inflammation at the sites of deposition of calcium pyrophosphate crystals, is at the same time one of the most widespread and least well-studied rheumatic diseases. Among the most pressing issues is the possibility of CPPD influencing the risk of cardiovascular diseases (CVDs) and mortality. The suspected causes contributing to the development of CVDs include microcrystalline inflammation and pathological vascular calcification, due to the common mechanisms of articular and vascular calcification. These assumptions are supported by data from several cross-sectional studies that have shown an independent direct association of CPPD with CVDs outcomes, but without the influence of CPPD on cardiovascular mortality. It is possible that the lack of association of CPPD with cardiovascular mortality with a high frequency of cardiovascular events at the same time is explained by the intake of colchicine, as well as the physiological anti-infective effects of interleukin 1. It is important to further search for mechanisms linking CPPD with CVDs and therapy aimed at preventing CVDs in this disease.
About the Authors
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
Maxim Eliseev
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать
M. N. Chikina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать
Ya. I. Kuzmina
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать
E. L. Nasonov
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Competing Interests:
Russian Federation
115522, Moscow, Kashirskoye Highway, 34A
Competing Interests:
Авторы несут полную ответственность за предоставление окончательной версии рукописи в печать
References
1. Fuller A, Cai K, Filippou G, Pascart T, Diaz-Torne C, Hensey O, et al. Experience and impact of crystal pyrophosphate deposition (CPPD) from a patient and caregiver perspective: A qualitative exploration from the OMERACT CPPD working group. Semin Arthritis Rheum. 2021;51(3):655-660. doi: 10.1016/j.semarthrit.2021.04.010
2. Pineda C, Sandoval H, Pérez-Neri I, Soto-Fajardo C, CarranzaEnríquez F. Calcium pyrophosphate deposition disease: Historical overview and potential gaps. Front Med (Lausanne). 2024;11:1380135. doi: 10.3389/fmed.2024.1380135
3. Asghari KM, Zahmatyar M, Seyedi F, Motamedi A, Zolfi M, Alamdary SJ, et al. Gout: Global epidemiology, risk factors, comorbidities and complications: A narrative review. BMC Musculoskelet Disord. 2024;25(1):1047. doi: 10.1186/s12891-024-08180-9
4. . Nasonov EL, Popkova TV, Novikova DS. Cardiovascular disease in rheumatic diseases. Terapevticheskii arkhiv. 2016;88(5):4 12 (In Russ.). doi: 10.17116/terarkh20168854-12
5. Manolis AS, Tzioufas AG. Cardio-rheumatology: Two collaborating disciplines to deal with the enhanced cardiovascular risk in autoimmune rheumatic diseases. Curr Vasc Pharmacol. 2020;18(6):533-537. doi: 10.2174/1570161118666200721145718
6. Pascart T, Filippou G, Lioté F, Sirotti S, Jauffret C, Abhishek A. Calcium pyrophosphate deposition disease. Lancet Rheumatol. 2024;6(11):e791-e804. doi: 10.1016/S2665-9913(24)00122-X
7. Yuan J, Xie Z, Pan B, Zhang J. Impact of gout on cardiovascular disease mortality: A meta-analysis. Z Rheumatol. 2024;83(Suppl 3):329-337. doi: 10.1007/s00393-024-01479-x
8. Timsans J, Palomäki A, Kauppi M. Gout and hyperuricemia: A narrative review of their comorbidities and clinical implications. J Clin Med. 2024;13(24):7616. doi: 10.3390/jcm13247616
9. Held J, Schwabl C, Haschka D, Maier S, Feuchtner G, Widmann G, et al. Major cardiovascular events in patients with cardiovascular monosodium urate deposits in atherosclerotic plaques. Rheumatology (Oxford). 2025;64(3):1443-1447. doi: 10.1093/rheumatology/keae240
10. Bashir M, Sherman KA, Solomon DH, Rosenthal A, Tedeschi SK. Cardiovascular disease risk in calcium pyrophosphate deposition disease: A nationwide study of veterans. Arthritis Care Res (Hoboken). 2023;75(2):277-282. doi: 10.1002/acr.24783
11. Drapkina OM, Kobalava ZhD, Shestakova MV, Bobkova IN, Efremovtseva MA, Villevalde SV, et al. Cardiovascular risk and chronic kidney disease: Strategies for cardiac and renal protection. Interdisciplinary consensus. Cardiovascular Therapy and Prevention. 2025;24(6):4466 (In Russ.). doi: 10.15829/1728-8800-2025-4466
12. Abhishek A, Doherty S, Maciewicz R, Muir K, Zhang W, Doherty M. Association between low cortical bone mineral density, soft-tissue calcification, vascular calcification and chondrocalcinosis: A case-control study. Ann Rheum Dis. 2014;73(11):1997- 2002. doi: 10.1136/annrheumdis-2013-203400
13. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386(6620):78-81. doi: 10.1038/386078a0. PMID: 9052783
14. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260- 1268. doi: 10.1101/gad.12.9.1260
15. Tedeschi SK, Huang W, Yoshida K, Solomon DH. Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. Ann Rheum Dis. 2022;81(9):1323-1329. doi: 10.1136/annrheumdis-2022-222387
16. Ramonda R, Musacchio E, Perissinotto E, Sartori L, Punzi L, Corti MC, et al. Prevalence of chondrocalcinosis in Italian subjects from northeastern Italy. The Pro.V.A. (PROgetto Veneto Anziani) study. Clin Exp Rheumatol. 2009;27(6):981-984.
17. Raza M, Rana MS, Arif M, Akinpelu T, Waheed A. Synovium to myocardium: A case of calcium pyrophosphate dihydrate crystal arthritis associated with myocardial infarction. Cureus. 2023;15(2):e34528. doi: 10.7759/cureus.34528
18. Williams CJ, Rosenthal AK. Pathogenesis of calcium pyrophosphate deposition disease. Best Pract Res Clin Rheumatol. 2021;35(4):101718. doi: 10.1016/j.berh.2021.101718
19. Nasonov EL. Role of interleukin-1 in human diseases: Pharmacotherapy prospects: A review. Terapevticheskii arkhiv. 2022;94(8):999-1005 (In Russ.). doi: 10.26442/00403660.2022.08.201781
20. Everett BM, MacFadyen JG, Thuren T, Libby P, Glynn RJ, Ridker PM. Inhibition of interleukin-1β and reduction in atherothrombotic cardiovascular events in the CANTOS trial. J Am Coll Cardiol. 2020;76(14):1660-1670. doi: 10.1016/j.jacc.2020.08.011
21. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: Exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535- 542. doi: 10.7326/M18-1167
22. Parperis K, Constantinou M, Lampi M, Bhattarai B. Acute coronary syndrome in calcium pyrophosphate deposition disease patients: A US inpatient care cohort study. Semin Arthritis Rheum. 2024;67:152464. doi: 10.1016/j.semarthrit.2024.152464
23. Mohammadnia N, Wesselink BE, Bax WA, Nidorf SM, Mosterd A, Fiolet ATL, et al. Cardiovascular benefit of colchicine in relation to baseline risk: A secondary analysis of the LoDoCo2 trial. J Am Heart Assoc. 2025;14(10):e038687. doi: 10.1161/JAHA.124.038687
24. Andreis A, Imazio M, Piroli F, Avondo S, Casula M, Paneva E, et al. Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: A systematic review and meta-analysis on 12 869 patients. Eur J Prev Cardiol. 2022;28(17):1916-1925. doi: 10.1093/eurjpc/zwab045
25. Nasonov EL, Drapkina OM. Colchicine: Repositioning an “ancient” medicine in the 21st century. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(5):445-464 (In Russ.). doi: 10.47360/1995-4484-2024-445-464
26. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al.; ESC Scientific Document Group. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi: 10.1093/eurheartj/ehae177
27. Li Y, Qiang R, Cao Z, Wu Q, Wang J, Lyu W. NLRP3 inflammasomes: Dual function in infectious diseases. J Immunol. 2024;213(4):407-417. doi: 10.4049/jimmunol.2300745
28. Baygozina EA, Dolgih VT, Sovalkin VI. Polymorphism of genes of interleukin-1 family as factor of pathogenesis of nosocomial pneumonia. Pathological Physiology and Experimental Therapy. 2015;59(4):66-72 (In Russ.)
29. Parperis K, Hadi M, Bhattarai B. Outcomes and resource utilization in calcium pyrophosphate deposition disease patients who underwent total knee arthroplasty: A cross-sectional analysis. Clin Rheumatol. 2022;41(6):1817-1824. doi: 10.1007/s10067-022-06101-6
Review
For citations:
Eliseev M.S., Chikina M.N., Kuzmina Ya.I., Nasonov E.L. Is calcium pyrophosphate crystal deposition disease a new disease in the list of rheumatic diseases with cardiovascular risk? Rheumatology Science and Practice. 2026;64(3):258-262. (In Russ.) https://doi.org/10.47360/1995-4484-2026-258-262
Views:
34
JATS XML
Email this article 